NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of...
Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025 )
Also on site :
- Iran top diplomat to meet UN nuclear chief in Cairo
- The world’s wealthiest dynasty is growing richer from Britain’s SEND crisis
- The Cast of a Raunchy Cult Favorite Sitcom Meets the Star of a Beloved Children's '90s TV Show — and the Internet Explodes